Medical House Share Discussion Threads

[wild bill] 10/12/2007 12:53

You're quiet Frenchie I see PJ is too.....

[red ninja] 30/11/2007 06:49

Is this what they call a double bottom ?
Probably a bit early to make that suggestion.

Bought some more yesterday as the story in the latest report
seemed very bullish. Hopefully I'm not deceived.

Even if the economy goes into recession health stocks
generaly provide a safe haven.

[philjeans] 14/11/2007 16:38

Firmed again after good volume of buys.

[geraldus] 13/11/2007 19:07

Since 2 November 07. for me.

[wild bill] 13/11/2007 17:45

Since when? Jan 07 or Jan 06

[geraldus] 13/11/2007 14:30

Medical stocks are good defensive plays in this sort of market.This one has turned out to be a nice little earner so far.

[philjeans] 13/11/2007 09:29

Slowly but surely, we're gaining ground daily in a falling market.

[philjeans] 12/11/2007 09:09

Ticking up again - more interest being shown.

[geraldus] 08/11/2007 14:18

With todays announcement it looks like another current partner has tightened their ties with MLH.They both must have high hopes in the product (%0}

[philjeans] 07/11/2007 13:42

Millions of shares changing hands today - stakebuilding.

Ticking up and a long way to go.

[geraldus] 05/11/2007 16:22

Possibly why there was such high volume last Friday,one of the rare times when I've managed to buy ahead of a rerating (hopefully).Looks like the orthopaeidic division is going which is a drag on the profits and now more income for the coffers.Investors Chronicle were buyers at 29p

[philjeans] 05/11/2007 12:22

Good news today and I've just grabbed 15k - looks an absolute steal now.

[geraldus] 03/11/2007 19:50

Yes Grupo my thoughts also,brokers forecasts I take as complete guesstimates though.

[grupo guitarlumber] 03/11/2007 16:53

not a holder,but perhaps things are turning round
and should start to get better.

[grupo guitarlumber] 03/11/2007 16:52

The Medical House FY pretax loss 1.29 mln stg; says confident of profit growth




LONDON (Thomson Financial) - The Medical House PLC said its pretax losses
for the year to end-June widened but that it remains confident of profit growth,
though the timing will depend on product launches.
The drug delivery technology specialist said it reported a pretax loss of
1.29 mln stg for the year to June 30, against a restated 1.16 mln stg a year
earlier. Its revenues declined to 5.1 mln stg from a restated 5.6 mln stg in the
year before, primarily due to the softening of demand in the orthopaedic
industry.
But the company said its prospects are excellent and sales in the drug
delivery division continued to grow.
It said the downward trend in revenue is now reversing and the results since
the company's year-end are up significantly from last year.



[e-mail]
sim/aku/jrr

[geraldus] 03/11/2007 12:07

Big volume yesterday,had a few myself,very quiet board,anyone out there interested in this?-G.Spotts

[waldron] 15/6/2007 17:47

where you bean marra

[wild bill] 15/6/2007 17:19

need some toons

[wild bill] 15/6/2007 17:19

Mr Kipling quiet in fact

[wild bill] 15/6/2007 11:53

quiet in here

[waldron] 27/3/2007 07:24

Medical House Notification of Shareholding


RNS Number:7493T
Medical House PLC
27 March 2007


For Immediate Release 27 March 2007





The Medical House plc (the "Company")



Notification of Shareholding



In accordance with Chapter 5 of the FSA's Disclosure and Transparency Rules, the
Company received notification on 26 March 2007 that following the disposal of
86,903 shares in the Company on 23 March 2007, F&C Asset Management plc now have
an interest in 1,785,406 ordinary shares of The Medical House plc, amounting to
2.97% of the issued share capital.





For further information please contact:


The Medical House [phone]
Mike Mason - Company Secretary

Nomura Code Securities [phone]
Wolf Dornbusch




This information is provided by RNS
The company news service from the London Stock Exchange
END

HOLDQLFLDXBZBBB

[grupo guitarlumber] 21/3/2007 10:04

Medical House(The Medical House wins Autoinjector development deal from EU worth up to 1 mln stg


LONDON (AFX) - Medical House PLC said it has been commissioned by a European
Government Agency to enter into a second phase of developing disposable
Autoinjector technology for the emergency administration of specific
pharmaceutical compounds.
The company will receive up to 1 mln stg on achieving certain milestones.
Medical House said it has to develop and manufacture devices for technical
assessment over an anticipated 12-month period, and this represents its largest
development project to-date.
[e-mail]
faj/lam

[ariane] 06/3/2007 07:16

Medical House Interim Results


RNS Number:3555S
Medical House PLC
06 March 2007


For Immediate Release 6 March 2007



The Medical House PLC
Interim Results for the six months ended 31 December 2006


The Medical House PLC ("TMH") (AIM:MLH) the drug delivery and orthopaedic
devices company, announces its interim results for the six months ended 31
December 2006.



* Financial Performance

* Operating loss reduced by 25% to #473,000 for period when compared
to six months ended 30th June 2006
* Turnover #2.7m (2005: #2.9m)
* Pre-tax loss before exceptional items #539,000 ( 2005: #392,000)


* Drug Delivery Systems
* 148% sales increase to #730,000 (2005: #294,000)
* #27m deal with major global pharmaceutical company, for customised
version of our ASI disposable autoinjector
* Discussions ongoing for further licence and development agreements


* Orthopaedic Instruments

* Turnover of #2.0m (2005: #2.7m) - in line with expectations
* Continued effect of major customer experiencing FDA delay -
adversely effecting order levels
* Restructuring continues to make Orthopaedic business more diverse


Executive Chairman, Ian Townsend, said:

"We are extremely pleased by the performance of our drug delivery business,
which continues to make excellent progress as illustrated by the licence and
supply agreement we signed in December 2006 for our ASI disposable autoinjector
technology, with a major pharmaceutical company. Our ASI autoinjector technology
continues to be favourably received and we remain confident that further
development, licence and supply contracts will be signed in due course."


For further information:
The Medical House PLC tel: [phone]
Ian Townsend, Executive Chairman www.themedicalhouse.com

Buchanan Communications tel: [phone]
Tim Anderson / Rebecca Skye Dietrich


Chairman's Statement

The Medical House specialises in the development and manufacture of innovative
medical devices.


The principal operating businesses are:

1. Drug delivery systems: Medical House Products Limited
2. Instruments and implants for the orthopaedic market: Eurocut Limited

We are pleased to report that our drug delivery business continues to make
excellent progress as illustrated by the significant development, licence and
supply agreement we signed in December 2006 for our ASI disposable autoinjector
technology. As anticipated when announcing our 2006 annual results on 10 October
2006, Eurocut has continued to find trading in its core orthopaedics market
difficult. Therefore, new markets have been targeted with some success but, as
expected, volumes from the new activities are low as it takes time to win the
confidence of a new customer base.

The drug delivery business is a major success in an area which has seen very
high valuations placed on companies with profiles similar to The Medical
House's. Our orthopaedics activities are based on specialist engineering
expertise, but the business is currently diversifying as a result of the soft
demand for orthopaedic instruments. The Directors believe that the contrasting
performances of the two divisions is causing confusion amongst investors which
is suppressing the value of the Group. The directors are therefore actively
pursuing a strategy to maximise shareholder value with respect to the
orthopaedic business.

In our results to 30th June 2006, we announced that we had received approaches
for the purchase of our needle-free insulin injector business. We continue to
actively explore the possibility of disposing of this element of our activities
which no longer fits our business model of licensing and supplying devices
solely to pharmaceutical and healthcare company clients.


Group Financials

The Group is reporting a pre-tax loss before reorganisation costs of #539,000
(2005: #392,000) on sales which were slightly lower at #2.7m (2005: #2.9m) for
the six months ended 31st December 2006. This represents a reduced loss to that
reported for the six months ended 30th June 2006.


Drug Delivery Division: Medical House Products Limited (MHP)

Sales in the six months grew by 148% to #730,000 (2005: #294,000) despite the
division not yet enjoying major benefits of the anticipated product launches for
pharmaceutical company partners' drugs with our needle-free and autoinjector
devices.

The highlight of the period was undoubtedly the signing of the development,
licence and supply agreement with projected sales of #27m, with a major global
pharmaceutical company, for a customised version of our ASI disposable
autoinjector. This agreement not only has significant financial benefits for the
company but also enhances our company's credibility in our marketplace. The
development phase of this project is progressing well.

Our ASI autoinjector technology continues to be favourably received and we
remain confident that further development, licence and supply contracts will be
signed in due course.

Our ASI device can be used in conjunction with almost any pre-filled syringe and
offers major economic, safety and convenience advantages by enabling patients to
self-inject their medications without any clinical expertise. This in turn
creates significant competitive advantages for pharmaceutical companies who
incorporate their injectable drug products within such a device. In the past
year a number of self-injected drugs have been successfully launched with
pre-filled, disposable autoinjectors and all indications are for this trend to
gain further momentum as newly-developed biologic drugs (which are more likely
to require injection) are brought to market. Our technology is also extremely
adaptable as it can be easily adjusted to vary volume, speed and depth of an
injection. This flexibility of the ASI technology allows us to provide clients
with a specific solution to their requirements and, as a result, most future
agreements for the ASI are likely to involve some form of customisation.

In addition to the contracts we have already announced, we have further
developed the ASI platform technology with designs well advanced for a "mini"
version of the device (for therapies which require users to carry their drugs
with them at all times) and a version which automatically mixes dry
formulations with liquid diluents, prior to automated injection. In addition to
our existing system for delivery of viscous (e.g. sustained release) drugs,
these variants within the ASI range of autoinjectors have significant commercial
potential and our intellectual property management strategy is focused on
protection of this innovation.

Sales growth in the short term largely depends on the demand for our clients'
drug products which are being partnered with our devices. These products are at
various stages of commercialisation but the timing of their commercial launches
is in the hands of our customers. However, with the development, licence and
supply agreements already in place, we remain very confident of a future of
sustained growth for many years to come.


Orthopaedic Division: Eurocut Limited

Sales in the six months to 31st December were #2m (2005: #2.7m) in line with the
expectations we communicated to shareholders in the 2006 year-end results. Sales
were held back due to a much quieter overall orthopaedic market which has
similarly affected our competitors in the orthopaedic instrumentation field. We
were also affected by the continued absence of the orders which have been
deferred due to a major customer experiencing delays in US FDA regulatory
approval. This particular position has not changed since our last announcement;
however, we continue to work closely with our customer on this product line.

During the last six months we incurred reorganisation costs of #56,000 due to
redundancy expenses, as we continue to restructure Eurocut into a diverse
business, serving a variety of markets and with several income streams. With the
appointment of additional business development staff and, whilst utilising our
existing skills and machinery, our non-orthopaedic orders are steadily
increasing and we fully expect this growth to gather momentum in the coming
months.

New customers invariably wish to see evidence of our capability to produce a
quality product in a timely manner. Consequently, small orders are typically
received in the first instance, followed by more regular, larger orders. During
the past six months we have completed a number of such initial orders for a
diverse range of products. Over the next six months we now expect to receive the
benefits of these efforts and the volume of our non-orthopaedic business should
steadily increase from here. The added advantage of the new areas we have
entered is that the margins we are able to achieve are generally much higher
than those currently available in orthopaedics.

With no signs yet of a major pick up in the orthopaedic market, the recovery in
Eurocut's sales and profits will come from these new markets, customers and
products. In order to demonstrate our commitment to our new customers in
different industries, we have formed a new company, TMH Precision Engineering,
which will be responsible for all non-medical work. A new website is being
created and a sales force, with experience in relevant markets has been
recruited. Eurocut, which has an established brand name in the medical world,
will supply only medical products.


Outlook

The drug delivery division will continue to progress on all fronts and we remain
very confident of its continued success in formalising further collaboration
agreements and partnerships. Short term results will be influenced by the pace
of the recovery at Eurocut, and the performance of the newly-formed TMH
Precision Engineering. Meanwhile, given the performance of our orthopaedic
operations, and the current depressed market valuation of the Group, the
Directors continue to review all strategic options for the orthopaedic and
needle-free businesses. Finally, I would like to thank all my colleagues who
have worked extremely hard to create a company of which they can all be very
proud.


Ian Townsend
Executive Chairman
6 March 2007